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SESSION INFORMATION
Background/Purpose:
Little is known about the long-term costs of lupus nephritis (LN). The annual and long-term
healthcare costs were compared between SLE patients with and without LN.
Methods:
Patients from 32 centres in 11 countries were enrolled in the Systemic Lupus International
Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis and provided annual
data on renal function, hospitalizations, dialysis, and utilization of medications and selected
procedures.  LN was diagnosed by renal biopsy or fulfillment of the American College of
Rheumatology (ACR) SLE classification criteria renal item.  Renal function was also assessed
annually based on estimated glomerular filtration rate (eGFR) or proteinuria (ePrU).  Annual
health resource utilization was costed using 2012 Canadian prices.  Annual costs associated with
renal function states were obtained from multiple regressions adjusting for age, race/ethnicity,
disease duration, SLICC centre location, SLEDAI-2K and SLICC/ACR Damage Index (excluding renal
components), and the SF-36.  5-year cumulative costs were estimated by determining annual costs
associated with each renal function state and then forecasting the expected duration in each
state. Durations were estimated using a relative risk regression model.
Results:
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1645 patients participated, 89.2% females, 48.8% Caucasian, mean age at diagnosis 34.8 years (SD
13.4), mean disease duration at enrollment 0.5 years (SD 0.3), and mean follow up 6.1 years (SD
3.3).  LN was diagnosed in 39.4% over follow up.  Health resource utilization and annual costs
(after adjustment using regression) were markedly higher in those with an eGFR < 30 ml/min or
with LN (Table 1).
 
Table 1.  Predicted Annual Health Costs Stratified by State of Renal Function
eGFR ePrU Lupus Nephritis
State Costs, Mean
95% CI
2012 CDN$
State Costs, Mean
95% CI
2012 CDN$
State Costs, Mean
95% CI
2012 CDN$
eGFR >60 ml/min
 
2234
(1503, 2965)
ePrU< 0.25g/d
 
2247
(1406, 3088)
No Lupus
Nephritis
1588
(726,2450)
eGFR 30-
60ml/min
 
3014
(1636, 4392)
ePrU 0.25-
3.0g/d
 
3424
(2287, 4561)
 Lupus
Nephritis
3876
(2949,4803)
eGFR < 30 ml/min
 
12551
(10301, 14801)
ePrU > 3.0 g/d
 
4703
(2128, 7278)
  
5-year cumulative costs stratified by baseline renal function state were calculated by multiplying
the annual costs associated with each state by the expected duration in that state (eGFR example
in Table 2).
 
Table 2. Expected Duration in Each Renal State over 5 Years
 Expected Duration in each State over 5 years
Baseline State Annual Costs
2012 CDN$
eGFR >60 ml/
min
eGFR 30-60
ml/min
eGFR < 30
ml/min
eGFR >60 ml/ min 2234 4.74 yrs 0.22 yrs 0.04 yrs
pdfcrowd.com
eGFR 30-60 ml/min 3014 2.60 yrs 1.88 yrs 0.52 yrs
eGFR < 30 ml/min 12551 1.03 yrs 1.09 yrs 2.88 yrs
Five year cumulative costs were greater in those with severely impaired eGFR or with LN at
baseline (Table 3).
 
Table 3. Predicted 5-Year Cumulative Health Costs Stratified by Baseline State of Renal Function
eGFR ePrU Lupus Nephritis
Baseline State Costs, Mean
95% CI
2012 CDN$
Baseline State Costs, Mean
95% CI
2012 CDN$
Baseline
State
Costs, Mean
95% CI
2012 CDN$
eGFR >60 ml/ min
 
11763
(7904,
15622)
ePrU< 0.25 g/d
 
12070
(7594,
16547)
No
Lupus
Nephritis
8663
(4331, 12995)
eGFR 30-60
ml/min
 
18008
(12348,
23667)
ePrU 0.25-3.0
g/d
 
13834
(8758,
18909)
Lupus
Nephritis
19380
(14745, 24015)
eGFR < 30 ml/min
 
41732
(32998,
50467)
ePrU > 3.0 g/d
 
15627
(9192,
22061)
  
 
Conclusion:
Patients with an eGFR <30ml/min and LN incur higher annual and 5-year cumulative costs.  By
estimating the expected duration in each renal function state and incorporating associated
annual costs, disease severity at presentation can be used to anticipate future healthcare costs,
critical knowledge for cost effectiveness evaluations of novel LN therapies.
Disclosure: M. Barber, Bristol-Myers Squibb, 2; J. G. Hanly, Bristol-Myers Squibb, 2; A. O'Keeffe,
Bristol-Myers Squibb, 2; L. Su, Bristol-Myers Squibb, 2; M. Urowitz, Bristol-Myers Squibb, 2; Y. St.
pdfcrowd.com
Bristol-Myers Squibb, 2; L. Su, Bristol-Myers Squibb, 2; M. Urowitz, Bristol-Myers Squibb, 2; Y. St.
Pierre, Bristol-Myers Squibb, 2; J. Romero-Diaz, Bristol-Myers Squibb, 2; C. Gordon, Bristol-Myers
Squibb, 2; S. C. Bae, Bristol-Myers Squibb, 2; S. Bernatsky, Bristol-Myers Squibb, 2; D. J. Wallace,
Bristol-Myers Squibb, 2; J. T. Merrill, Bristol-Myers Squibb, 2; D. A. Isenberg, Bristol-Myers Squibb,
2; A. Rahman, Bristol-Myers Squibb, 2; E. M. Ginzler, Bristol-Myers Squibb, 2; P. R. Fortin, Bristol-
Myers Squibb, 2; D. D. Gladman, Bristol-Myers Squibb, 2; J. Sanchez-Guerrero, Bristol-Myers
Squibb, 2; M. Petri, Bristol-Myers Squibb, 2; I. N. Bruce, Bristol-Myers Squibb, 2; M. A. Dooley,
BriThe SLICC research network received funding for this study from Bristol-Myers Squibb, 2; R.
Ramsey-Goldman, Bristol-Myers Squibb, 2; C. Aranow, Bristol-Myers Squibb, 2; G. S. Alarcon,
Bristol-Myers Squibb, 2; W. W. Chatham, Bristol-Myers Squibb, 2; K. Steinsson, Bristol-Myers
Squibb, 2; O. Nived, Bristol-Myers Squibb, 2; G. K. Sturfelt, Bristol-Myers Squibb, 2; S. Manzi,
Bristol-Myers Squibb, 2,Bristol-Myers Squibb, 2; M. Khamashta, Bristol-Myers Squibb, 2; R. F. van
Vollenhoven, Bristol-Myers Squibb, 2; A. Zoma, Bristol-Myers Squibb, 2; M. Ramos-Casals, Bristol-
Myers Squibb, 2; G. Ruiz-Irastorza, Bristol-Myers Squibb, 2; S. S. Lim, Bristol-Myers Squibb, 2; T.
Stoll, Bristol-Myers Squibb, 2; M. Inanc, Bristol-Myers Squibb, 2; K. C. Kalunian, Bristol-Myers
Squibb, 2; D. L. Kamen, Bristol-Myers Squibb, 2; P. Maddison, Bristol-Myers Squibb, 2; C. A.
Peschken, Bristol-Myers Squibb, 2; S. Jacobsen, Bristol-Myers Squibb, 2; A. Askanase, Bristol-
Myers Squibb, 2; J. P. Buyon, Bristol-Myers Squibb, 2; C. Theriault, Bristol-Myers Squibb, 2; K.
Thompson, Bristol-Myers Squibb, 2; V. Farewell, Bristol-Myers Squibb, 2; A. E. Clarke, Bristol-
Myers Squibb, 2.
To cite this abstract in AMA style:
Barber M, Hanly JG, O'Keeffe A, Su L, Urowitz M, St. Pierre Y, Romero-Diaz J, Gordon C, Bae SC,
Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin PR, Gladman DD,
Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcon GS,
Chatham WW, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta M, van Vollenhoven RF,
Zoma A, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL,
Maddison P, Peschken CA, Jacobsen S, Askanase A, Buyon JP, Theriault C, Thompson K,
Farewell V, Clarke AE. Economic Evaluation of Lupus Nephritis in an International Inception
Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those
with and without Nephritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10).
http://acrabstracts.org/abstract/economic-evaluation-of-lupus-nephritis-in-an-international-
inception-cohort-comparing-the-hospitalization-medication-dialysis-and-procedure-costs-of-
those-with-and-without-nephritis/. Accessed January 17, 2017.
ACR Meeting Abstracts - http://acrabstracts.org/abstract/economic-evaluation-of-lupus-nephritis-
in-an-international-inception-cohort-comparing-the-hospitalization-medication-dialysis-and-
procedure-costs-of-those-with-and-without-nephritis/
